Anastasia S. Turlak
Anastasia S. Turlak has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrii A. Granov
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies
5 shared publications - Aleksey Aleksandrovich Polikarpov
ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» МЗ РФ
4 shared publications - Aleksey V. Kozlov
Russian scientific center of radiology and surgical technologies named after academician A.M. Granov
4 shared publications - Pavel G. Tarazov
Russian scientific center of radiology and surgical technologies named after academician A.M. Granov
4 shared publications - Andrey V. Moiseenko
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
3 shared publications - Aleksandr N. Polyakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- Open Access
- 19 December 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (4) , 122-128
Long-term survival of patients with advanced intrahepatic cholangiocarcinoma after regional chemotherapy
The paper presents the results of successful regional chemotherapy applied in the treatment of two patients with unresectable cholangiocellular carcinoma. In the first case, a 57-year-old female patient with metastatic cholangiocarcinoma demonstrated an overall survival of 8 years following a regimen that combined systemic and regional chemotherapy. Within 6.5 years, the patient underwent 25 cycles of endovascular treatment, three of which were conducted post-relief of mechanical jaundice using a stent. The adverse effects of chemotherapy, characterized by mild anemia and thrombocytopenia, necessitated no additional treatment. In the second case, a 73-year-old patient with bilobed tumor underwent 31 cycles of regional chemotherapy in combination with systemic therapy; the overall survival accounted for 5 years. The combination of regional and systemic chemotherapy can be considered safe and effective for the management of advanced cholangiocellular carcinoma. The combination of endovascular chemoembolization and chemoinfusion is regarded as promising.
- 19 December 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (4) , 122-128
Open AccessLong-term survival of patients with advanced intrahepatic cholangiocarcinoma after regional chemotherapy
The paper presents the results of successful regional chemotherapy applied in the treatment of two patients with unresectable cholangiocellular carcinoma. In the first case, a 57-year-old female patient with metastatic cholangiocarcinoma demonstrated an overall survival of 8 years following a regimen that combined systemic and regional chemotherapy. Within 6.5 years, the patient underwent 25 cycles of endovascular treatment, three of which were conducted post-relief of mechanical jaundice using a stent. The adverse effects of chemotherapy, characterized by mild anemia and thrombocytopenia, necessitated no additional treatment. In the second case, a 73-year-old patient with bilobed tumor underwent 31 cycles of regional chemotherapy in combination with systemic therapy; the overall survival accounted for 5 years. The combination of regional and systemic chemotherapy can be considered safe and effective for the management of advanced cholangiocellular carcinoma. The combination of endovascular chemoembolization and chemoinfusion is regarded as promising.
- Open Access
- 18 October 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Visualization in Medicine
- Vol. 6 (2) , 30-37
АРТЕРИАЛЬНЫЕ РЕНТГЕНЭНДОВАСКУЛЯРНЫЕ МЕТОДЫ ЛЕЧЕНИЯ НЕРЕЗЕКТАБЕЛЬНОЙ ВНУТРИПЕЧЕНОЧНОЙ ХОЛАНГИОКАРЦИНОМЫ (ОБЗОР ЛИТЕРАТУРЫ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ)
Холангиоцеллюлярный рак является вторым по распространенности первичным злокачественным новообразованием печени. Радикальное удаление опухоли возможно лишь у 30–40% больных. Системная химиотерапия (СХТ) — основной метод лечения нерезектабельной внутрипеченочной холангиокарциномы (ХКЦ), однако частота объективного ответа не превышает40%, а медиана выживаемости составляет 12 месяцев. Артериальные рентгенэндоваскулярные методы могут являться альтернативой СХТ у неоперабельных больных. В обзоре представлены данные литературы и собственный опыт применения методов регионарной химиотерапии нерезектабельной внутрипеченочной ХКЦ. Cholangiocellular carcinoma is the second most common primary liver malignancy. Radical resection is possible only in 30–40% sick. Systemic chemotherapy (SCT) is the basic treatment for unresectable intrahepatic cholangiocarcinoma (ICC), but the objective response rate does not exceed 40%, and the median survival is no more than 12 months. Arterial endovascular methods may be an alternative treatment to SCT. The review presents literature data and our experience in the use of regional chemotherapy in unresectable ICC.
- 18 October 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Visualization in Medicine
- Vol. 6 (2) , 30-37
Open AccessАРТЕРИАЛЬНЫЕ РЕНТГЕНЭНДОВАСКУЛЯРНЫЕ МЕТОДЫ ЛЕЧЕНИЯ НЕРЕЗЕКТАБЕЛЬНОЙ ВНУТРИПЕЧЕНОЧНОЙ ХОЛАНГИОКАРЦИНОМЫ (ОБЗОР ЛИТЕРАТУРЫ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ)
Холангиоцеллюлярный рак является вторым по распространенности первичным злокачественным новообразованием печени. Радикальное удаление опухоли возможно лишь у 30–40% больных. Системная химиотерапия (СХТ) — основной метод лечения нерезектабельной внутрипеченочной холангиокарциномы (ХКЦ), однако частота объективного ответа не превышает40%, а медиана выживаемости составляет 12 месяцев. Артериальные рентгенэндоваскулярные методы могут являться альтернативой СХТ у неоперабельных больных. В обзоре представлены данные литературы и собственный опыт применения методов регионарной химиотерапии нерезектабельной внутрипеченочной ХКЦ. Cholangiocellular carcinoma is the second most common primary liver malignancy. Radical resection is possible only in 30–40% sick. Systemic chemotherapy (SCT) is the basic treatment for unresectable intrahepatic cholangiocarcinoma (ICC), but the objective response rate does not exceed 40%, and the median survival is no more than 12 months. Arterial endovascular methods may be an alternative treatment to SCT. The review presents literature data and our experience in the use of regional chemotherapy in unresectable ICC.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-12
Clinical significance of germline mutations in BRCA1/2 gene in pancreatic ductal adenocarcinoma (literature review)
Pancreatic ductal adenocarcinoma occupies a leading position in mortality among other malignant neoplasms. The five-year survival of patients is less than 9 %. Risk of a tumor development increases with a mutation in the BRCA gene, however, the effect of this mutation on the clinical course of the disease has been poorly studied and is of certain scientific and practical interest. A review of the world literature on the clinical significance of germline mutations – the risks of malignancy, the choice of treatment tactics – is presented.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-12
Clinical significance of germline mutations in BRCA1/2 gene in pancreatic ductal adenocarcinoma (literature review)
Pancreatic ductal adenocarcinoma occupies a leading position in mortality among other malignant neoplasms. The five-year survival of patients is less than 9 %. Risk of a tumor development increases with a mutation in the BRCA gene, however, the effect of this mutation on the clinical course of the disease has been poorly studied and is of certain scientific and practical interest. A review of the world literature on the clinical significance of germline mutations – the risks of malignancy, the choice of treatment tactics – is presented.
- Open Access
- 11 April 2023
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 14 (1) , 84-94
Intraductal photodynamic therapy and its combination with intra-arterial chemoinfusion in the treatment of inoperable patients with Klatskin tumor
Background: A palliative or symptomatic treatment is indicated for 7080% of patients with Klatskins tumor because of the advanced lesion volume and the patients grave condition. Hepatic arterial infusion chemotherapy, chemoembolization, radioembolization are successfully used in the treatment of hepatocellular carcinoma and liver metastases. Aim: to estimate the immediate and long-term results of photodynamic therapy (PDT) and its combination with hepatic arterial infusion in inoperable patients with Klatskin tumors. Methods: Between 2010 and 2021, 83 palliative PDT sessions (from 1 to 8, average 2.4) were performed in 82 patients as a single treatment or in combination with hepatic arterial infusion. In all cases, percutaneous transhepatic biliary drainage was previously performed; no chemotherapy was applied. Two groups of 48 patients were stratified according to the ECOG status (23) and the numbers of PDT sessions (no more than two). The treatment group of the combination therapy consisted of 24 patients (13 male, 11 female) aged 38 to 85 (mean 63) years with the ECOG status of 24 (mean 2.4). This group received PDT with hepatic arterial infusion using a GemCis regimen. On average, 1.4 PDT sessions were performed, the treatment started on the 89th (27225) day after the biliary drainage. The hepatic arterial infusion was performed on the 2d3th day after the PDT. The control group received only PDT and consisted of 24 patients (13 male, 11 female) aged 51 to 83 (66 on average) years, with the ECOG status of 23 (mean 2.6). On average, 1.4 PDT sessions were performed, starting on the 106th (32405) day after the biliary drainage. Results: There were no serious adverse events associated with PDT in both groups. Toxic complications of hepatic arterial infusion were observed in 13 of 24 patients (54%): III grade hematological (54%) and gastrointestinal (69%); all were eliminated with medical therapy. Complications of the percutaneous transhepatic biliary drainage in three patients (hemobilia, n=2, and sepsis, n=1) were estimated as grade III by the CIRSE classification (2017) and successfully treated without surgery. In the combination treatment group, the overall mean survival and median survival were higher than those in the control group: 327.939.8 days (10.9 mo) versus 246.931.2 days (8.2 mo) and 275 days versus 244 days. However, these differences did not reach the statistical significance (p=0.12). Conclusions: PDT is a safe method of a palliative treatment of critically ill patients with Klatskin tumor (ECOG 23). PDT alone has limited clinical efficacy. A combination of PDT and hepatic arterial infusion does not cause serious complications and may increase the survival rates.
- 11 April 2023
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 14 (1) , 84-94
Open AccessIntraductal photodynamic therapy and its combination with intra-arterial chemoinfusion in the treatment of inoperable patients with Klatskin tumor
Background: A palliative or symptomatic treatment is indicated for 7080% of patients with Klatskins tumor because of the advanced lesion volume and the patients grave condition. Hepatic arterial infusion chemotherapy, chemoembolization, radioembolization are successfully used in the treatment of hepatocellular carcinoma and liver metastases. Aim: to estimate the immediate and long-term results of photodynamic therapy (PDT) and its combination with hepatic arterial infusion in inoperable patients with Klatskin tumors. Methods: Between 2010 and 2021, 83 palliative PDT sessions (from 1 to 8, average 2.4) were performed in 82 patients as a single treatment or in combination with hepatic arterial infusion. In all cases, percutaneous transhepatic biliary drainage was previously performed; no chemotherapy was applied. Two groups of 48 patients were stratified according to the ECOG status (23) and the numbers of PDT sessions (no more than two). The treatment group of the combination therapy consisted of 24 patients (13 male, 11 female) aged 38 to 85 (mean 63) years with the ECOG status of 24 (mean 2.4). This group received PDT with hepatic arterial infusion using a GemCis regimen. On average, 1.4 PDT sessions were performed, the treatment started on the 89th (27225) day after the biliary drainage. The hepatic arterial infusion was performed on the 2d3th day after the PDT. The control group received only PDT and consisted of 24 patients (13 male, 11 female) aged 51 to 83 (66 on average) years, with the ECOG status of 23 (mean 2.6). On average, 1.4 PDT sessions were performed, starting on the 106th (32405) day after the biliary drainage. Results: There were no serious adverse events associated with PDT in both groups. Toxic complications of hepatic arterial infusion were observed in 13 of 24 patients (54%): III grade hematological (54%) and gastrointestinal (69%); all were eliminated with medical therapy. Complications of the percutaneous transhepatic biliary drainage in three patients (hemobilia, n=2, and sepsis, n=1) were estimated as grade III by the CIRSE classification (2017) and successfully treated without surgery. In the combination treatment group, the overall mean survival and median survival were higher than those in the control group: 327.939.8 days (10.9 mo) versus 246.931.2 days (8.2 mo) and 275 days versus 244 days. However, these differences did not reach the statistical significance (p=0.12). Conclusions: PDT is a safe method of a palliative treatment of critically ill patients with Klatskin tumor (ECOG 23). PDT alone has limited clinical efficacy. A combination of PDT and hepatic arterial infusion does not cause serious complications and may increase the survival rates.
- Open Access
- 31 March 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (1) , 71-79
Klatskin Tumor: Difficulties in Diagnosis and Preoperative Staging. Clinical Observation
Klatskin’s tumor is a rare malignant neoplasm characterized by the absence of specific symptoms, challenges in verification and difficulties in assessing the true extent of the tumor. We present a clinical case of a patient with hilar cholangiocarcinoma. The patient received almost the entire modern complex of radiologic examinations for preoperative staging. However, concominant cholangitis, hard-to-reach anatomical localization and tumor’s creeping-growth distorted the results of instrumental studies. The true volume of the lesion was detected only intraoperatively and resulted in an expansion of liver resection volume.
- 31 March 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (1) , 71-79
Open AccessKlatskin Tumor: Difficulties in Diagnosis and Preoperative Staging. Clinical Observation
Klatskin’s tumor is a rare malignant neoplasm characterized by the absence of specific symptoms, challenges in verification and difficulties in assessing the true extent of the tumor. We present a clinical case of a patient with hilar cholangiocarcinoma. The patient received almost the entire modern complex of radiologic examinations for preoperative staging. However, concominant cholangitis, hard-to-reach anatomical localization and tumor’s creeping-growth distorted the results of instrumental studies. The true volume of the lesion was detected only intraoperatively and resulted in an expansion of liver resection volume.
- Open Access
- 26 October 2022
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 13 (3) , 25-31
Intra-arterial chemotherapy in the treatment of inoperable patients with Klatskin tumor: preliminary results
Background: Surgical resection is the treatment of choice for Klatskin tumor, when possible, but unfortunately, many patients present with the late-stage and unresectable disease. A large number of studies have confirmed that arterial chemotherapy is safe and effective for the palliative treatment of primary and secondary hepatic malignancies. Aim: To evaluate the safety and efficacy of hepatic arterial infusion in patients with Klatskin tumor. Methods: Between 2010 and 2021, 14 of 119 patients with inoperable Klatskin tumor were treated with hepatic arterial infusion of GemCis at the A.M. Granov RRCRST. All the patients had obstructive jaundice and received percutaneous transhepatic biliary drainage. Chemotherapy was started when the serum bilirubin level became normal (averagely on the 106th day from percutaneous transhepatic biliary drainage). In total, 19 (from 1 to 4 per patient) hepatic arterial infusion cycles were performed. Results: Percutaneous transhepatic biliary drainage complications such as cholangitis (n=2) and local peritonitis (n=1) developed in 3 patients (21%) and were successfully treated using minimally invasive techniques. The toxicity of chemotherapy was observed in 8 of 14 patients (57%): III degree hematological toxicity (43%) and gastrointestinal toxicity (50%); these complications were cured by medical therapy. The overall mean survival was 286 days (9.6 months), the median survival was 283 days (9.4 months). Conclusions: Our preliminary results show that hepatic arterial infusion in patients with Klatskin tumor is safe, but has limited effectiveness. The combination of arterial infusion with other methods such as radiotherapy, intra-ductal photodynamic therapy, radiofrequency ablation, target therapy, should be investigated.
- 26 October 2022
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 13 (3) , 25-31
Open AccessIntra-arterial chemotherapy in the treatment of inoperable patients with Klatskin tumor: preliminary results
Background: Surgical resection is the treatment of choice for Klatskin tumor, when possible, but unfortunately, many patients present with the late-stage and unresectable disease. A large number of studies have confirmed that arterial chemotherapy is safe and effective for the palliative treatment of primary and secondary hepatic malignancies. Aim: To evaluate the safety and efficacy of hepatic arterial infusion in patients with Klatskin tumor. Methods: Between 2010 and 2021, 14 of 119 patients with inoperable Klatskin tumor were treated with hepatic arterial infusion of GemCis at the A.M. Granov RRCRST. All the patients had obstructive jaundice and received percutaneous transhepatic biliary drainage. Chemotherapy was started when the serum bilirubin level became normal (averagely on the 106th day from percutaneous transhepatic biliary drainage). In total, 19 (from 1 to 4 per patient) hepatic arterial infusion cycles were performed. Results: Percutaneous transhepatic biliary drainage complications such as cholangitis (n=2) and local peritonitis (n=1) developed in 3 patients (21%) and were successfully treated using minimally invasive techniques. The toxicity of chemotherapy was observed in 8 of 14 patients (57%): III degree hematological toxicity (43%) and gastrointestinal toxicity (50%); these complications were cured by medical therapy. The overall mean survival was 286 days (9.6 months), the median survival was 283 days (9.4 months). Conclusions: Our preliminary results show that hepatic arterial infusion in patients with Klatskin tumor is safe, but has limited effectiveness. The combination of arterial infusion with other methods such as radiotherapy, intra-ductal photodynamic therapy, radiofrequency ablation, target therapy, should be investigated.
- Open Access
- 1 January 2017
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 24 (1) , 9-14
PROFESSOR ILYA YAKOVLEV (ON THE 120TH ANNIVERSARY)
В 2016 г. исполняется 120 лет со дня рождения Ильи Ильича Яковлева. Статья посвящена биографии Ильи Ильича, описан его научно-исследовательский путь, отмечены основные достижения в области акушерства и гинекологии. Приведена характеристика его клинического труда. Также повествуется об его преподавательской деятельности.
- 1 January 2017
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 24 (1) , 9-14
Open AccessPROFESSOR ILYA YAKOVLEV (ON THE 120TH ANNIVERSARY)
В 2016 г. исполняется 120 лет со дня рождения Ильи Ильича Яковлева. Статья посвящена биографии Ильи Ильича, описан его научно-исследовательский путь, отмечены основные достижения в области акушерства и гинекологии. Приведена характеристика его клинического труда. Также повествуется об его преподавательской деятельности.